Enzyme Replacement Therapy for Gaucher Disease
Customize your policy alerts
Sign up for healthspring Policy RX501.190 alerts
Get alerted when Policy RX501.190 changes without checking for updates manually.
Monitor payer policy activity
Coverage of imiglucerase, taliglucerase alfa, and velaglucerase alfa for specified Gaucher disease manifestations in adults and pediatric patients, limited to FDA-labeled indications and subject to benefit plan and applicable state requirements.
A new medical policy was established for enzyme replacement therapy used in the treatment of Gaucher disease.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.